Halozyme Therapeutics (HALO) Finished Goods (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Finished Goods data on file, last reported at $113.4 million in Q1 2026.

• On a quarterly basis, Finished Goods fell 20.85% year-over-year to $113.4 million in Q1 2026; TTM through Mar 2026 was $113.4 million, a 20.85% decrease from a year earlier, with the FY2025 full-year figure at $144.5 million, up 1.06% from the prior year.
• Finished Goods for Q1 2026 stood at $113.4 million, down from $144.5 million in the prior quarter.
• Over the last five years, Finished Goods for HALO reached as high as $164.9 million in Q2 2025 and fell as low as $31.2 million in Q1 2022.
• Historically, Finished Goods has averaged $96.6 million across 5 years, with a median of $95.8 million in 2024.
• Across the five-year window, Finished Goods jumped 122.79% in 2024 and slipped 20.85% in 2026, its largest moves.
• Year by year, Finished Goods stood at $46.0 million in 2022, then surged by 52.12% to $69.9 million in 2023, then surged by 104.41% to $142.9 million in 2024, then increased by 1.06% to $144.5 million in 2025, then retreated by 21.52% to $113.4 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $113.4 million in Q1 2026, $144.5 million in Q4 2025, and $161.6 million in Q3 2025.